Effect of a Non-Invasive Brain Stimulation Technique on Smoking Cessation Behaviors
| Status: | Completed |
|---|---|
| Conditions: | Smoking Cessation, Tobacco Consumers |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 64 |
| Updated: | 3/23/2019 |
| Start Date: | January 1, 2018 |
| End Date: | November 21, 2018 |
In this pilot study, the feasibility of using tDCS (a non-invasive brain stimulation
technique) while performing a task requiring cognitive flexibility will be examined in
smokers and initial data will be collected regarding the effect of tDCS on smoking cessation
behaviors. Smokers will be randomized to receive either active or sham tDCS daily for 5 days
after which they will attempt to quit smoking. Smoking behavior after the attempted quit date
will be assessed at four weekly visits.
technique) while performing a task requiring cognitive flexibility will be examined in
smokers and initial data will be collected regarding the effect of tDCS on smoking cessation
behaviors. Smokers will be randomized to receive either active or sham tDCS daily for 5 days
after which they will attempt to quit smoking. Smoking behavior after the attempted quit date
will be assessed at four weekly visits.
Inclusion Criteria:
- Be between the ages of 18 and 64
- Smoked (on average) at least 5 cigarettes per day
- Be motivated to quit smoking
Exclusion Criteria:
- Unstable medical or psychiatric conditions
- Any medical conditions with neurological sequelae
- History of loss of consciousness of greater than 30 minutes duration or loss of
consciousness with neurological sequelae
- Have any medical condition or use any medication that would either increase risk of
subjects participating in this study (e.g., medications that lower the seizure
threshold) or that would impact measures of interest (e.g. smoking cessation
medications).
- Are pregnant or planning to become pregnant during the study
- Current use of pacemaker, intracranial electrodes or implanted defibrillator
We found this trial at
1
site
Minneapolis, Minnesota 55455
Principal Investigator: Michael Kotlyar, PharmD
Phone: 612-625-1160
Click here to add this to my saved trials
